pharmaphorum
FEBRUARY 3, 2022
Legislation is already in place allowing companies to grow the plant for medicinal purposes under license, doctors have been able to prescribe it since 2017 with full reimbursement from health insurers.
The Pharma Data
DECEMBER 20, 2020
Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Druggist
DECEMBER 28, 2020
The Government recently announced the reclassification of fexofenadine 120mg, which will be available as General sale Medication (GSL), sold as branded products – Allevia 120mg tablets. When to speak to a pharmacist or a doctor before taking Allevia tablets? Until now, fexofenadine was a prescription-only medication.
Pharmacy Checkers
DECEMBER 10, 2020
In 2017, a group of activists, policy professionals, lawyers, and doctors came together in Brussels at the RightsCon conference to draft the Brussels Principles on the Sale of Medicines Over the Internet. FDA because its label is not the one required for the sale of that drug in the U.S. It’s the exact same drug sold here.
pharmaphorum
JUNE 6, 2022
Approval in that broader patient range could unlock $3 billion in additional sales for Enhertu, according to analysts at Credit Suisse. billion upfront to license rights to Enhertu in a deal that could be worth up to $6.9 billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved. AZ paid $1.4
pharmaphorum
SEPTEMBER 13, 2021
AbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get its hands on a gene therapy for wet age-related macular degeneration (AMD) and other eye diseases. AbbVie – which is also putting up $1.38 The transaction is expected to close by the end of 2021.
pharmaphorum
APRIL 20, 2021
“People living with MS need access to a range of different treatment options so they can work with their doctor to find the one that’s best for them,” said David Martin, chief executive of the Multiple Sclerosis Trust. billion in sales in 2028. billion by 2028. It was backed by NICE for NHS use in July 2018.
Expert insights. Personalized for you.
114 
Let's personalize your content